Seven Fleet Capital Management LP Buys 6,509 Shares of Ascendis Pharma A/S $ASND

Seven Fleet Capital Management LP raised its stake in Ascendis Pharma A/S (NASDAQ:ASND) by 114.8% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,179 shares of the biotechnology company’s stock after acquiring an additional 6,509 shares during the period. Ascendis Pharma A/S makes up about 0.9% of Seven Fleet Capital Management LP’s portfolio, making the stock its 26th biggest holding. Seven Fleet Capital Management LP’s holdings in Ascendis Pharma A/S were worth $2,786,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently modified their holdings of the stock. Parallel Advisors LLC grew its holdings in shares of Ascendis Pharma A/S by 94.9% during the 1st quarter. Parallel Advisors LLC now owns 304 shares of the biotechnology company’s stock worth $70,000 after purchasing an additional 148 shares in the last quarter. Perceptive Advisors LLC raised its stake in Ascendis Pharma A/S by 41.6% in the first quarter. Perceptive Advisors LLC now owns 1,531,421 shares of the biotechnology company’s stock valued at $350,282,000 after purchasing an additional 450,000 shares in the last quarter. EverSource Wealth Advisors LLC lifted its position in Ascendis Pharma A/S by 34.0% during the first quarter. EverSource Wealth Advisors LLC now owns 272 shares of the biotechnology company’s stock worth $62,000 after purchasing an additional 69 shares during the period. Eagle Health Investments LP bought a new stake in Ascendis Pharma A/S during the first quarter worth about $19,819,000. Finally, Empowered Funds LLC grew its stake in Ascendis Pharma A/S by 39.3% during the first quarter. Empowered Funds LLC now owns 51,135 shares of the biotechnology company’s stock worth $11,696,000 after buying an additional 14,438 shares in the last quarter.

Ascendis Pharma A/S Stock Down 2.9%

Shares of ASND opened at $243.91 on Friday. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.72 and a current ratio of 1.00. Ascendis Pharma A/S has a 52 week low of $167.27 and a 52 week high of $282.15. The stock has a market capitalization of $15.21 billion, a price-to-earnings ratio of 28.13 and a beta of 0.37. The stock has a fifty day moving average of $244.95 and a 200-day moving average of $234.90.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its quarterly earnings data on Thursday, May 7th. The biotechnology company reported $0.32 earnings per share for the quarter, topping analysts’ consensus estimates of $0.21 by $0.11. The firm had revenue of $285.45 million for the quarter, compared to the consensus estimate of $362.47 million. As a group, sell-side analysts anticipate that Ascendis Pharma A/S will post 4.49 earnings per share for the current fiscal year.

Insider Transactions at Ascendis Pharma A/S

In other news, insider Flemming Steen Jensen sold 19,460 shares of the company’s stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $238.49, for a total value of $4,641,015.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Jean Jacques Bienaime acquired 400 shares of the company’s stock in a transaction that occurred on Tuesday, May 26th. The stock was acquired at an average price of $237.80 per share, with a total value of $95,120.00. Following the acquisition, the director owned 400 shares in the company, valued at $95,120. The trade was a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Company insiders own 40.00% of the company’s stock.

Wall Street Analysts Forecast Growth

ASND has been the topic of several recent analyst reports. Citigroup started coverage on shares of Ascendis Pharma A/S in a report on Monday, May 18th. They issued a “buy” rating and a $355.00 target price on the stock. Bank of America increased their price target on shares of Ascendis Pharma A/S from $262.00 to $292.00 and gave the stock a “buy” rating in a research report on Thursday, April 16th. Oppenheimer restated an “outperform” rating on shares of Ascendis Pharma A/S in a research report on Tuesday, June 9th. Royal Bank Of Canada upped their target price on Ascendis Pharma A/S from $275.00 to $280.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 7th. Finally, Evercore reaffirmed an “outperform” rating and issued a $329.00 target price on shares of Ascendis Pharma A/S in a report on Friday, May 15th. Two analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $296.72.

About Ascendis Pharma A/S

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.